Spanish Pharma Industry Appeals Local Drug Funding Decisions
This article was originally published in The Pink Sheet Daily
Spain's drug industry appeals against a court ruling allowing local drug funding decisions.
You may also be interested in...
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.
Pricing pressure in Europe is hardly new, but it became a much bigger concern in 2010. The last 18 months have seen some of the most severe and certainly the most numerous, price cuts across the region. Although individual European countries represent only a small share of Big Pharma revenues, the EU as a whole is the world's second-largest market in sales terms, only slightly smaller than the U.S.
The Swedish government's proposals to encourage domestic innovation by having government purchasers suggest earlier in companies' research what kinds of new services are needed is drawing support, albeit somewhat tentatively, from the nation's pharma industry.